 Genprex Inc NASDAQ: GNPX is trading higher Monday after the company announced it received U.S. Food and Drug Administration Fast Track Designation FTD for REQORSA Immunogene Therapy in combination with Merck Co Incs NYSE: MRK Keytruda for the treatment of non-small cell lung cancer. The FTD is for patients with histologically-confirmed unresectable stage 3 or 4 non-small cell lung cancer whose disease progressed after treatment with Keytruda. 